AMICUS THERAPEUTICS INC (FOLD) Stock Price, Quote, News and Overview
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
FOLD Quote, Performance and Key Statistics
6.67
-0.01 (-0.15%)
The current stock price of FOLD is 6.67 USD. In the past month the price decreased by -16.62%. In the past year, price decreased by -35.87%.
FOLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About FOLD
Company Profile
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 499 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Company Info
AMICUS THERAPEUTICS INC
47 Hulfish St.
Princeton NEW JERSEY 19104 US
CEO: John F. Crowley
Employees: 499
Phone: 16096622000
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the stock price of AMICUS THERAPEUTICS INC today?
The current stock price of FOLD is 6.67 USD. The price decreased by -0.15% in the last trading session.
What is the ticker symbol for AMICUS THERAPEUTICS INC stock?
The exchange symbol of AMICUS THERAPEUTICS INC is FOLD and it is listed on the Nasdaq exchange.
On which exchange is FOLD stock listed?
FOLD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMICUS THERAPEUTICS INC stock?
18 analysts have analysed FOLD and the average price target is 17.03 USD. This implies a price increase of 155.38% is expected in the next year compared to the current price of 6.67. Check the AMICUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMICUS THERAPEUTICS INC worth?
AMICUS THERAPEUTICS INC (FOLD) has a market capitalization of 2.05B USD. This makes FOLD a Mid Cap stock.
How many employees does AMICUS THERAPEUTICS INC have?
AMICUS THERAPEUTICS INC (FOLD) currently has 499 employees.
What are the support and resistance levels for AMICUS THERAPEUTICS INC (FOLD) stock?
AMICUS THERAPEUTICS INC (FOLD) has a resistance level at 8.39. Check the full technical report for a detailed analysis of FOLD support and resistance levels.
Is AMICUS THERAPEUTICS INC (FOLD) expected to grow?
The Revenue of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 19.78% in the next year. Check the estimates tab for more information on the FOLD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMICUS THERAPEUTICS INC (FOLD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FOLD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FOLD, evaluating the profitability, health, valuation and growth aspects
- AMICUS THERAPEUTICS INC (FOLD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMICUS THERAPEUTICS INC (FOLD) Sales and EPS estimates to see what analysts future expectations are.
- AMICUS THERAPEUTICS INC (FOLD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMICUS THERAPEUTICS INC (FOLD) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMICUS THERAPEUTICS INC (FOLD) Stock Chart to make your own analysis
- AMICUS THERAPEUTICS INC (FOLD) Latest news and press-releases to stay up to date.
Does AMICUS THERAPEUTICS INC (FOLD) stock pay dividends?
FOLD does not pay a dividend.
When does AMICUS THERAPEUTICS INC (FOLD) report earnings?
AMICUS THERAPEUTICS INC (FOLD) will report earnings on 2025-05-21, before the market open.
What is the Price/Earnings (PE) ratio of AMICUS THERAPEUTICS INC (FOLD)?
AMICUS THERAPEUTICS INC (FOLD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
What is the Short Interest ratio of AMICUS THERAPEUTICS INC (FOLD) stock?
The outstanding short interest for AMICUS THERAPEUTICS INC (FOLD) is 6.47% of its float. Check the ownership tab for more information on the FOLD short interest.
FOLD Technical Analysis
FOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FOLD. While FOLD is still in line with the averages on profitability rating, there are concerns on its financial health.
FOLD Financial Highlights
Over the last trailing twelve months FOLD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 64.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.15% | ||
| ROE | -28.91% | ||
| Debt/Equity | 2.01 |
FOLD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to FOLD. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 118.26% and a revenue growth 19.78% for FOLD